Beta-adrenergic pathway activation enhances aggressiveness and inhibits stemness in head and neck cancer

Registro completo de metadados
MetadadosDescriçãoIdioma
Autor(es): dc.contributorUniversidade Estadual Paulista (UNESP)-
Autor(es): dc.creatorLopes-Santos, Gabriela-
Autor(es): dc.creatorBernabé, Daniel Galera-
Autor(es): dc.creatorMiyahara, Glauco Issamu-
Autor(es): dc.creatorTjioe, Kellen Cristine-
Data de aceite: dc.date.accessioned2025-08-21T23:16:00Z-
Data de disponibilização: dc.date.available2025-08-21T23:16:00Z-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2022-04-29-
Data de envio: dc.date.issued2021-08-01-
Fonte completa do material: dc.identifierhttp://dx.doi.org/10.1016/j.tranon.2021.101117-
Fonte completa do material: dc.identifierhttp://hdl.handle.net/11449/229165-
Fonte: dc.identifier.urihttp://educapes.capes.gov.br/handle/11449/229165-
Descrição: dc.descriptionChronic stress leads to the activation of the beta-adrenergic pathway. Its activation has been implicated in the progression of different types of cancer but its role on head and neck squamous cell carcinomas (HNSCCs) remains undefined. The aim of this study was to investigate the influence of the beta-adrenergic pathway activation in the progression of HNSCCs and offer a panel of potential treatments for patients with the active beta-adrenergic pathway. Five hundred and twenty TCGA patients with primary HNSCCs were divided in two groups: ADRB2low / SLC6A2low and ADRB2high / SLC6A2high. Differentially expressed genes (DEGs) were identified through differential expression analysis. The association of clinicopathological and genomic features between the groups was analyzed using a bioinformatic approach. Potential drugs for treatment of HNSCC were identified based on the DEGs. There was association between ADRB2 and SLC6A2 expressions with age, race, tumor site, histologic grade, perineural invasion, and HPV p16 status. It was identified 898 DEGs between the groups. High ADRB2/SLC6A2 expression stimulated HNSCC proliferation, adhesion, invasion, and angiogenesis. On the other hand, genes related to cell stemness were downregulated in patients with activation of the beta- adrenergic pathway. Finally, 56 FDA-approved antineoplastic and immunotherapeutic drugs were identified as potential targets for the personalized treatment.-
Descrição: dc.descriptionFundação de Amparo à Pesquisa do Estado de São Paulo (FAPESP)-
Descrição: dc.descriptionOral Oncology Center São Paulo State University (Unesp), School of Dentistry, 1193 José Bonifácio St.-
Descrição: dc.descriptionPsychoneuroimmunology Laboratory Psychosomatic Research Center Oral Oncology Center São Paulo State University (Unesp), School of Dentistry, 1193 José Bonifácio St-
Descrição: dc.descriptionOral Oncology Center São Paulo State University (Unesp), School of Dentistry, 1193 José Bonifácio St.-
Descrição: dc.descriptionPsychoneuroimmunology Laboratory Psychosomatic Research Center Oral Oncology Center São Paulo State University (Unesp), School of Dentistry, 1193 José Bonifácio St-
Descrição: dc.descriptionFAPESP: 2016/00051–2-
Idioma: dc.languageen-
Relação: dc.relationTranslational Oncology-
???dc.source???: dc.sourceScopus-
Palavras-chave: dc.subjectBeta-adrenergic receptors-
Palavras-chave: dc.subjectHead and Neck Squamous Cell Carcinoma-
Palavras-chave: dc.subjectNorepinephrine Transport Protein-
Palavras-chave: dc.subjectPsychological stress-
Título: dc.titleBeta-adrenergic pathway activation enhances aggressiveness and inhibits stemness in head and neck cancer-
Tipo de arquivo: dc.typelivro digital-
Aparece nas coleções:Repositório Institucional - Unesp

Não existem arquivos associados a este item.